SIMEIGELU peptide, telaprevir peptide collectively lower prices, weight loss drug competition moves forward to 2026.

At the end of 2025, a price war initiated by multinational pharmaceutical companies Novo Nordisk and Eli Lilly quietly unfolded on government procurement platforms and e-commerce platforms, with actual transaction prices almost "slashed in half" compared to six months ago. "This is not just a simple year-end promotion, but a precise strategic race," several industry experts told reporters. They said that before the impending expiration of the Sitagliptin patent in 2026 and the opening of the "battle for territory" with domestic innovative drugs and biosimilars, the giants are trying to build a defense barrier through pre-set price anchors.